S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TSHA · Taysha Gene Therapies, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Taysha Gene Therapies Inc (TSHA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$4.12
-0.00
(-0.12%)
● At close: October 21 at 4:00:00 PM EDT
$4.13
+0.01
(+0.24%)
Overnight:
11:05:38 PM EDT
DAY'S RANGE
$4.12
$4.05
$4.26
52-WEEK RANGE
$4.12
$3.46
$7.30
What's happening
- TSHA is down 0.12% today, trading at $4.12. — Live quote
- Volume today (319,078) is well below its 3-month average of 3,665,970. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.14 actual vs. $-0.12 estimated (-17.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TSHA
-25.27%
vs S&P 500
-38.05%
1-YEAR RETURN
TSHA
-12.92%
vs S&P 500
-27.48%
6-MONTH RETURN
TSHA
-30.92%
3-MONTH RETURN
TSHA
-27.51%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.14
Est. $-0.12
MISS -17.7%
2026-04-26 (Q1 2026)
$-0.12
Est. $-0.10
MISS -20.5%
2026-01-26 (Q4 2025)
$-0.08
Est. $-0.10
BEAT +18.5%
2025-10-26 (Q3 2025)
$-0.09
Est. $-0.09
BEAT +0.0%
Valuation Measures & Ratios
Enterprise Value4$934.8M
Forward P/E5—
PEG Ratio6-0.43
Price / Sales (TTM1)137.19
Price / Book75.62
EV4 / Revenue95.65
EV4 / EBITDA—
Profit Margin-780.33%
Operating Margin-782.50%
Return on Equity (ROE8)-56.19%
Return on Assets (ROA9)-41.84%
Avg Volume (3M)3,665,970
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.44B | $1.57B | $1.19B | $690.0M | $371.4M |
| P/E | -16.42 | -12.74 | -11.13 | -7.27 | -4.03 |
| Price/Sales | 1229.29 | 367.18 | 195.44 | 95.99 | 43.12 |
| Price/Book | 6.30 | 7.43 | 5.42 | 2.77 | 6.75 |
| EV/Revenue | 1024.79 | 314.10 | 154.87 | 58.19 | 34.51 |
| ROE | -38.39% | -58.30% | -48.71% | -38.14% | -167.17% |
| ROA | -31.60% | -41.14% | -33.70% | -28.46% | -66.52% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short55,020,663
Change from Prior Settlement+7.03%
% of Float—
Days to Cover (Short Ratio)11.15
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -780.3%. Finnhub fundamentals ↗
- Trailing 52-week price return is -12.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TSHA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.0M | $2.3M | $1.8M | $1.1M | $3.4M |
| Operating income | -$47.3M | -$43.5M | -$34.0M | -$26.8M | -$21.4M | -$25.9M | -$21.3M | -$24.3M |
| Net income | -$46.6M | -$42.4M | -$32.7M | -$26.9M | -$21.5M | -$25.5M | -$20.9M | -$24.1M |
| EPS (diluted) | $-0.13 | $-0.12 | $-0.09 | $-0.09 | $-0.08 | $-0.10 | $-0.09 | $-0.10 |
| EPS (basic) | $-0.13 | $-0.12 | $-0.09 | $-0.09 | $-0.08 | $-0.10 | $-0.09 | $-0.10 |
| Operating margin | — | — | — | -$1.3K | -$931 | -$1.4K | -$1.9K | -$713 |
| Net margin | — | — | — | -$1.4K | -$935 | -$1.4K | -$1.9K | -$705 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $470.4M | $300.4M | $343.3M | $316.6M | $333.3M | $138.4M | $160.4M | $180.2M |
| Total liabilities | $83.2M | $88.4M | $96.4M | $97.6M | $84.6M | $83.3M | $88.8M | $91.4M |
| Stockholders' equity | $387.3M | $211.9M | $246.9M | $219.0M | $248.7M | $55.1M | $71.5M | $88.8M |
| Total current assets | $461.4M | $282.2M | $324.6M | $300.0M | $316.3M | $120.7M | $142.1M | $161.6M |
| Total current liabilities | $26.0M | $20.1M | $26.6M | $28.6M | $25.3M | $22.6M | $26.2M | $29.3M |
| Cash & equivalents | $455.4M | $276.6M | $319.8M | $297.3M | $312.8M | $116.6M | $139.0M | $157.7M |
| Other current assets | $851.0K | $1.0M | $802.0K | $456.0K | $657.0K | $536.0K | $308.0K | $465.0K |
| Property, plant & equipment | $2.4M | $6.5M | $6.7M | $6.8M | $7.0M | $7.2M | $7.5M | $7.6M |
| Other non-current assets | $106.0K | $181.0K | $183.0K | $184.0K | $186.0K | $188.0K | $217.0K | $220.0K |
| Accounts payable | $9.2M | $4.6M | $6.3M | $5.4M | $7.7M | $4.3M | $3.6M | $4.9M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | $5.5M | $5.5M | $7.5M | $9.8M | $11.8M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | $49.3M | $49.0M | $50.1M | $50.9M | $41.1M | $42.5M | $43.9M | $43.0M |
| Other non-current liabilities | $1.6M | $1.6M | $1.6M | $1.6M | $1.4M | $1.2M | $1.3M | $1.4M |
| Common stock & paid-in capital | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | -$800.3M | -$753.7M | -$711.3M | -$683.4M | -$650.7M | -$623.8M | -$602.3M | -$583.5M |
| Accumulated other comprehensive income (loss) | $769.0K | $985.0K | -$192.0K | -$1.1M | -$699.0K | -$2.3M | -$4.0M | -$2.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.4M | -$40.9M | -$26.7M | -$24.2M | -$20.2M | -$22.0M | -$18.3M | -$21.6M |
| Investing cash flow | $1.0K | -$3.0M | -$247.0K | -$48.0K | $62.0K | -$371.0K | $13.0K | -$35.0K |
| Financing cash flow | $216.7M | $711.0K | $49.6M | $8.8M | $216.3M | -$52.0K | -$357.0K | $6.6M |
| Free cash flow | -$40.4M | -$40.9M | -$27.0M | -$24.3M | -$20.2M | -$22.4M | -$18.3M | -$21.6M |
| Capital expenditures | -$1.0K | $24.0K | $250.0K | $108.0K | $2.0K | $378.0K | -$2.0K | $35.0K |
| Share-based compensation | $5.8M | $5.5M | $3.5M | $3.3M | $3.2M | $3.3M | $3.2M | $3.4M |
| Change in accounts payable | $4.6M | $1.3M | -$2.1M | -$1.9M | $3.0M | $923.0K | -$1.5M | -$3.8M |
| Other investing activities | — | — | -$3.0K | -$60.0K | -$64.0K | -$7.0K | -$11.0K | — |
| Other financing activities | $75.0K | $19.0K | -$90.0K | -$285.0K | $118.0K | -$80.0K | $43.0K | -$167.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M |
| EPS (diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| EPS (basic) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 |
| Operating margin | -$1.1K | -$1.1K | -$469 | -$6.5K | — |
| Net margin | -$1.1K | -$1.1K | -$722 | -$6.6K | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M |
| Stockholders' equity | $246.9M | $71.5M | $74.9M | $949.0K | $95.4M |
| Total current assets | $324.6M | $142.1M | $149.9M | $96.4M | $159.6M |
| Total current liabilities | $26.6M | $26.2M | $36.8M | $62.8M | $51.7M |
| Cash & equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M |
| Other current assets | $802.0K | $308.0K | $292.0K | $466.0K | $863.0K |
| Property, plant & equipment | $6.7M | $7.5M | $10.8M | $15.0M | $50.6M |
| Other non-current assets | $183.0K | $217.0K | $304.0K | $1.3M | $1.1M |
| Accounts payable | $6.3M | $3.6M | $6.4M | $10.9M | $21.8M |
| Deferred revenue (current) | — | $9.8M | $18.1M | $33.6M | — |
| Other current liabilities | — | — | — | — | $1.5M |
| Long-term debt | $50.1M | $43.9M | $40.5M | $38.0M | $37.2M |
| Other non-current liabilities | $1.6M | $1.3M | $1.6M | $4.1M | $3.7M |
| Common stock & paid-in capital | $3.0K | $2.0K | $2.0K | $1.0K | — |
| Retained earnings | -$711.3M | -$602.3M | -$513.0M | -$401.4M | -$235.6M |
| Accumulated other comprehensive income (loss) | -$192.0K | -$4.0M | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$93.1M | -$81.2M | -$73.0M | -$88.4M | -$117.0M |
| Investing cash flow | -$604.0K | -$363.0K | -$7.4M | -$24.9M | -$21.6M |
| Financing cash flow | $274.6M | $76.7M | $136.4M | $52.1M | $39.1M |
| Free cash flow | -$93.8M | -$81.6M | -$76.9M | -$109.0M | -$132.3M |
| Capital expenditures | $738.0K | $374.0K | $3.9M | $20.6M | $15.3M |
| Share-based compensation | $13.3M | $13.1M | $7.9M | $18.0M | $18.2M |
| Change in accounts payable | -$153.0K | -$2.9M | -$2.3M | -$7.8M | $14.5M |
| Other investing activities | -$134.0K | -$11.0K | -$17.0K | $61.0K | — |
| Other financing activities | -$337.0K | -$167.0K | -$229.0K | -$1.0M | -$514.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TSHA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers70.3%
Shares Outstanding369,044,040
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | $162.7M | 6.47% | +10.1% | 2026-08-14 |
| RA CAPITAL MANAGEMENT, L.P. | 23,555,648 | $160.4M | 6.38% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 22,713,118 | $154.7M | 6.15% | +1.5% | 2026-08-14 |
| BlackRock, Inc. | 20,691,927 | $140.9M | 5.61% | +12.7% | 2026-08-07 |
| Vestal Point Capital, LP | 19,415,000 | $132.2M | 5.26% | +7.9% | 2026-08-14 |
| Morgan Stanley | 16,487,479 | $112.3M | 4.47% | -8.2% | 2026-08-11 |
| RTW INVESTMENTS, LP | 13,560,258 | $92.3M | 3.67% | -0.9% | 2026-08-14 |
| FMR LLC | 13,336,413 | $90.8M | 3.61% | -6.9% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,478,595 | $85.0M | 3.38% | +22.0% | 2026-06-30 |
| State Street Corp | 11,421,920 | $77.8M | 3.10% | +1.9% | 2026-08-07 |
| Siren, L.L.C. | 9,846,579 | $67.1M | 2.67% | +11.5% | 2026-08-13 |
| Octagon Capital Advisors LP | 9,693,244 | $66.0M | 2.63% | +9.4% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 6,560,394 | $44.7M | 1.78% | +18.6% | 2026-08-12 |
| Polar Capital Holdings Plc | 5,117,133 | $34.8M | 1.39% | -9.5% | 2026-08-14 |
| MPM BioImpact LLC | 4,500,000 | $30.6M | 1.22% | +0.0% | 2026-08-14 |
| D. E. Shaw & Co., Inc. | 4,398,652 | $30.0M | 1.19% | -0.6% | 2026-08-14 |
| BAKER BROS. ADVISORS LP | 4,004,756 | $27.3M | 1.09% | +0.0% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 3,975,605 | $27.1M | 1.08% | +534.7% | 2026-08-14 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 3,885,501 | $26.5M | 1.05% | +34.8% | 2026-08-13 |
| Casdin Capital, LLC | 3,250,000 | $22.1M | 0.88% | +0.0% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3,140,009 | $21.4M | 0.85% | +55.3% | 2026-06-30 |
| ADAR1 Capital Management, LLC | 3,040,466 | $20.7M | 0.82% | +2.0% | 2026-08-14 |
| Pictet Asset Management Holding SA | 2,770,701 | $18.9M | 0.75% | +14242.6% | 2026-07-30 |
| Aberdeen Group plc | 2,327,152 | $15.8M | 0.63% | +127.9% | 2026-07-31 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2,250,000 | $15.3M | 0.61% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-02 to 2026-07-10
Recent transactions
- Insiders have net sold 200,000 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Nagendran Sukumar (President and Head of R&D) — Open market sale of 200,000 shares on 2026-07-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)200,000 sh(1 txns)
Net Shares-200,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | Open market sale | 2026-07-10 | 200,000 |
| Stalfort John A III | Reporting person | Grant / award | 2026-06-01 | 21,335 |
| Donenberg Phillip B. | Reporting person | Grant / award | 2026-06-01 | 21,335 |
| Long Alison S | Reporting person | Grant / award | 2026-06-01 | 21,335 |
| Sepp-Lorenzino Laura | Reporting person | Grant / award | 2026-06-01 | 21,335 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Open market sale | 2026-02-04 | 1,655 |
| Nolan Sean P. | Chief Executive Officer | Open market sale | 2026-01-26 | 41,312 |
| Manning Paul B | Reporting person | Open market purchase | 2025-05-30 | 750,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-10 | Nagendran Sukumar | President and Head of R&D | Open market sale | 200,000 | $6.24 |
| 2026-06-01 | Stalfort John A III | Reporting person | Grant / award | 21,335 | $0.00 |
| 2026-06-01 | Donenberg Phillip B. | Reporting person | Grant / award | 21,335 | $0.00 |
| 2026-06-01 | Long Alison S | Reporting person | Grant / award | 21,335 | $0.00 |
| 2026-06-01 | Sepp-Lorenzino Laura | Reporting person | Grant / award | 21,335 | $0.00 |
| 2026-04-10 | Nagendran Sukumar | President and Head of R&D | Option exercise | 19,021 | $1.71 |
| 2026-04-10 | Nagendran Sukumar | President and Head of R&D | Open market sale | 200,000 | $4.46 |
| 2026-02-04 | Alam Kamran | CHIEF FINANCIAL OFFICER | Open market sale | 1,655 | $4.52 |
| 2026-01-26 | Nagendran Sukumar | President and Head of R&D | Open market sale | 26,918 | $4.61 |
| 2026-01-26 | Nolan Sean P. | Chief Executive Officer | Open market sale | 41,312 | $4.61 |
| 2026-01-26 | Alam Kamran | CHIEF FINANCIAL OFFICER | Open market sale | 23,849 | $4.61 |
| 2026-01-23 | Nagendran Sukumar | President and Head of R&D | Open market sale | 89,132 | $4.75 |
| 2026-01-23 | Nolan Sean P. | Chief Executive Officer | Open market sale | 136,789 | $4.75 |
| 2026-01-23 | Alam Kamran | CHIEF FINANCIAL OFFICER | Open market sale | 78,968 | $4.75 |
| 2026-01-12 | Alam Kamran | CHIEF FINANCIAL OFFICER | Grant / award | 359,000 | $0.00 |
| 2026-01-12 | Nolan Sean P. | Chief Executive Officer | Grant / award | 1,008,000 | $0.00 |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Option exercise | 111,324 | $0.70 |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Option exercise | 88,676 | $1.71 |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Open market sale | 200,000 | $4.71 |
| 2026-01-12 | Nagendran Sukumar | President and Head of R&D | Grant / award | 427,000 | $0.00 |
| 2025-12-01 | Nagendran Sukumar | President and Head of R&D | Option exercise | 260,047 | $1.71 |
| 2025-12-01 | Nagendran Sukumar | President and Head of R&D | Open market sale | 260,047 | $4.51 |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Option exercise | 70,172 | $0.70 |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Option exercise | 39,953 | $1.71 |
| 2025-11-28 | Nagendran Sukumar | President and Head of R&D | Open market sale | 110,125 | $4.75 |
| 2025-09-10 | Nagendran Sukumar | President and Head of R&D | Option exercise | 41,150 | $0.70 |
| 2025-09-10 | Nagendran Sukumar | President and Head of R&D | Open market sale | 200,000 | $3.23 |
| 2025-08-21 | Nagendran Sukumar | President and Head of R&D | Open market sale | 57,054 | $2.85 |
| 2025-08-21 | Alam Kamran | CHIEF FINANCIAL OFFICER | Open market sale | 54,491 | $2.85 |
| 2025-06-02 | Stalfort John A III | Reporting person | Grant / award | 56,623 | $0.00 |
| 2025-06-02 | Donenberg Phillip B. | Reporting person | Grant / award | 56,623 | $0.00 |
| 2025-06-02 | Long Alison S | Reporting person | Grant / award | 56,623 | $0.00 |
| 2025-06-02 | Sepp-Lorenzino Laura | Reporting person | Grant / award | 56,623 | $0.00 |
| 2025-05-30 | Manning Paul B | Reporting person | Open market purchase | 750,000 | $2.75 |
| 2025-03-11 | Alam Kamran | CHIEF FINANCIAL OFFICER | Tax withholding | 29,843 | $1.69 |
| 2025-01-02 | Nolan Sean P. | Chief Executive Officer | Grant / award | 892,500 | $0.00 |
| 2025-01-02 | Nagendran Sukumar | President and Head of R&D | Grant / award | 324,500 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:09 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-10 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-22 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-02 | 8-K | 2026-06-01 | View on SEC.gov → |
| 2026-05-06 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-06 | 8-K | 2026-05-06 | View on SEC.gov → |
Recent news
Headlines about TSHA (Taysha Gene Therapies, Inc.). Links open the publisher — we don’t host full articles.
-
Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative
Simply Wall Street · 2026-10-20 -
Taysha Gene Therapies, Inc. (TSHA) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Does Rett Trial Progress Change The Bull Case For Taysha Gene Therapies Stock?
Simply Wall Street · 2026-10-19 -
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Yahoo · 2026-10-19 -
TSHA Oct 2026 11.000 call (TSHA261016C00011000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
TSHA Drops ‘Mi Casa’ EP, Shares ‘Another Planet’ Video
EDMTunes · 2026-10-16 -
TSHA Apr 2027 4.000 call (TSHA270416C00004000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
TSHA Apr 2027 9.000 call (TSHA270416C00009000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16
No headlines in this category right now — try “All”.